Why the study?
Angiosarcoma outcomes have not improved in decades, and integrating its heterogeneous mutational landscape with existing disease models is essential to identify potential therapeutic vulnerabilities.
This review synthesizes the current understanding of the genomic landscape and preclinical models of angiosarcoma to help identify potential therapeutic vulnerabilities for this rare and aggressive cancer.
May inform targeted therapy research in angiosarcoma; leaves open clinical translation pending prospective validation.
Angiosarcoma is a cancer that develops in blood or lymphatic vessels that presents a significant clinical challenge due to its rarity and aggressive features. Clinical outcomes have not improved in decades, highlighting a need for innovative therapeutic strategies to treat the disease. Genetically, angiosarcomas exhibit high heterogeneity and complexity with many recurrent mutations. However, recent studies have identified some common features within anatomic and molecular subgroups. To identify potential therapeutic vulnerabilities, it is essential to understand and integrate the mutational landscape of angiosarcoma with the models that exist to study the disease. In this review, we will summarize the insights gained from reported genomic alterations in molecular and anatomic subtypes of angiosarcoma, discuss several potential actionable targets, and highlight the preclinical disease models available in the field.
No takes yet. Share an insight, caveat, or question.
Benton et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: